Ceravolo
Maurizio Cantore, G. Fiorentini, Gabriele Luppi et al. · Journal of Chemotherapy · 2004
Gemcitabine is considered the gold standard treatment for unresectable pancreatic adenocarcinoma. Intra-arterial drug administration had shown some interesting results in small phase II studies. In this study, patients were randomly assigned to receive gemcitabine at a dose of 1,000 mg/m2 over 30 minutes intravenously weekly for 7 weeks, followed by 1 week of rest, then weekly for 3 weeks every 4 weeks or FLEC: 5-fluoruracil 1,000 mg/m2, leucovorin 100 mg/m2, epirubicin 60 mg/m2, carboplatin 300 mg/m2 infused bolus intra-arterially into celiac axis at a 3-week interval 3 times or 5-fluorouracil 400 mg/m2 plus folinic acid 20 mg/m2 for 5 days every 4 weeks for 6 cycles. The primary endpoint was overall survival, while time to treatment failure, response rate, clinical benefit response were secondary endpoints. Sixty-seven patients were randomly allocated gemcitabine and 71 were allocated FLEC intra-arterially. Patients treated with FLEC lived for significantly longer than patients on gemcitabine (p=0.036). Survival at 1 year increased from 21% in the gemcitabine group to 35% in the FLEC group. Median survival was 7.9 months in the FLEC group and 5.8 months in the gemcitabine group. Median time to treatment failure was longer with FLEC (5.3 vs 4.2 months for FLEC vs gemcitabine respectively; p=0.013). Clinical benefit was similar in both groups (17.9% for gemcitabine and 26.7% for FLEC; p=NS). CT-scan partial response was similar in both groups (5.9% for gemcitabine and 14% for FLEC; p=NS). Toxicity profiles were different. Compared with gemcitabine, the FLEC regimen given intra-arterially improved survival in patients with unresectable pancreatic adenocarcinoma.
Cited by 25 works. doi:10.1179/joc.2004.16.6.589
Authors
- Maurizio Cantore
- G. Fiorentini
- Gabriele Luppi
- Gerado Rosati
- Roberto Caudana
- E. Piazza
- G. Comella
- C. Ceravolo
- L. Miserocchi
- Andrea Mambrini
- Alfonso Del Freo
- Donatella Zamagni
- Carla Rabbi
- Maurizio Marangolo
References
- Cancer statistics, 2000
- Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
- Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues.
- Cell Surface P-Glycoprotein Associated with Multidrug Resistance in Mammalian Cell Lines
- Expression of Multidrug Resistance Gene in Human Cancers
- Modulation of Activity of the Promoter of the Human MDR 1 Gene by Ras and p53
- Patterns of failure after curative resection of pancreatic carcinoma
- An investigational new drug treatment program for patients with gemcitabine
- Glutathione S-transferases and drug resistance
- Pancreatic adenocarcinomas frequently show p53 gene mutations.